GDRX GoodRx
- 4.550
- +0.270+6.31%
- 4.600
- +0.050+1.10%
GoodRx News
Citi Maintains GoodRx(GDRX.US) With Buy Rating, Cuts Target Price to $6.25
GoodRx Holdings Is Maintained at Overweight by Keybanc
GoodRx Holdings Analyst Ratings
RBC Capital Maintains GoodRx(GDRX.US) With Buy Rating, Cuts Target Price to $6
KeyBanc Maintains GoodRx(GDRX.US) With Buy Rating, Cuts Target Price to $6
KeyBanc Cuts Price Target on GoodRx Holdings to $6 From $7, Keeps Overweight Rating
Mizuho Securities Maintains GoodRx(GDRX.US) With Hold Rating
TD Cowen Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $10
Truist Financial Maintains GoodRx(GDRX.US) With Hold Rating
GoodRx Holdings: Buy Rating Reaffirmed Amid Leadership Stability and Growth Prospects
GoodRx Holdings Analyst Ratings
Morgan Stanley Maintains Equal-Weight on GoodRx Holdings, Lowers Price Target to $6
Morgan Stanley Maintains GoodRx(GDRX.US) With Hold Rating, Cuts Target Price to $6
Citi Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $7
Wells Fargo Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $9
BofA Securities Maintains GoodRx(GDRX.US) With Sell Rating, Maintains Target Price $4.5
Sell Rating Maintained for GoodRx Holdings Amid Volatility and Strategic Challenges
Positive Outlook for GoodRx Holdings Under New Leadership: Buy Rating and 52.5% Potential Return
Mizuho Initiates GoodRx Holdings at Neutral With $5 Price Target
Analysts Conflicted on These Healthcare Names: Ionis Pharmaceuticals (IONS) and GoodRx Holdings (GDRX)
No Data